Lakefront Biotherapeutics Nv
Clinical trials sponsored by Lakefront Biotherapeutics Nv, explained in plain language.
-
New pill shows promise for rare muscle disease
Disease control CompletedThis study tested an oral medication called GLPG3667 in 40 adults with dermatomyositis, a rare autoimmune disease that causes muscle weakness and skin rashes. Participants took the drug or a placebo daily for 24 weeks to see if it improves muscle and skin symptoms. The goal is to…
Phase: PHASE2 • Sponsor: Lakefront Biotherapeutics NV • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
New oral drug shows promise in taming lupus flares
Disease control CompletedThis study tested an experimental daily pill, GLPG3667, in 186 adults with active systemic lupus erythematosus (SLE). The goal was to see if the drug could reduce lupus disease activity better than a placebo over 32 and 48 weeks. Researchers also monitored safety and how the body…
Phase: PHASE2 • Sponsor: Lakefront Biotherapeutics NV • Aim: Disease control
Last updated May 20, 2026 11:53 UTC